Targeting BRD9 in treatment-resistant prostate cancer
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2210222
- Recipient
-
Purdue University UEI YRXVL4JYCEF5
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $1,144,362
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- West Lafayette, IN, USA
Award details come from USAspending.gov.
About this award
Purdue University will use a $1.14 million project grant from the Department of the Army Medical Command to target BRD9 in treatment-resistant prostate cancer. The grant was awarded on August 1, 2022 under the Military Medical Research and Development program (CFDA 12.420). For a three-year period ending July 31, 2025, Purdue researchers will investigate medical solutions for prostate cancer that does not respond to standard therapies by focusing on the role of the BRD9 gene. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through innovative research and battlefield medical solutions.
Quick answers
Who received award W81XWH2210222?
W81XWH2210222 was awarded to Purdue University by Medical Command (Department of the Army) on August 1, 2022.
How much is award W81XWH2210222 worth?
$1,144,362 has been obligated on W81XWH2210222.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award